LIGAND PHARMACEUTICALS INC files 10-Q

Ligand Pharmaceuticals reported a net loss of $13.3 million for the first quarter of 2026, a significant improvement from a $42.5 million net loss in the same period of 2025, driven by increased royalty revenues and a substantial decrease in research and development expenses. The company also announced a definitive agreement to acquire XOMA for approximately $739 million in cash, expected to close in the third quarter of 2026.